Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

The company plans to create a new category of cellular medicines offering functional cures for metabolic and endocrine ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company and its vulnerability to soaring demand for weight-loss drugs.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Yields on European government bonds remained elevated, with the German 10-year bund yield hitting its highest level in six ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Veteran investment manager Terry Smith has dumped his underperforming £22.5bn fund’s stake in Diageo after almost 15 years owing to concerns over the drinks maker’s new management team and the threat ...

The fund benefits from Baillie Gifford’s bold attitude but a portfolio shake-up has made it much more appealing to investors ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...